MARKET

IMUX

IMUX

Immunic Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.27
-0.42
-3.31%
After Hours: 12.52 +0.25 +2.04% 19:27 07/10 EDT
OPEN
12.63
PREV CLOSE
12.69
HIGH
12.64
LOW
12.05
VOLUME
151.36K
TURNOVER
--
52 WEEK HIGH
19.05
52 WEEK LOW
4.190
MARKET CAP
183.66M
P/E (TTM)
-3.1613
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMUX stock price target is 48.25 with a high estimate of 58.00 and a low estimate of 40.00.

EPS

IMUX News

More
3 Strong Buy Micro-Cap Stocks That Offer Attractive Returns
TipRanks · 07/05 11:02
ImmunoGen (IMGN) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/24 18:46
Immunic to Join the Russell 3000
Benzinga · 06/22 10:36
Immunic, Inc. to Join Russell 3000® Index
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the company is set to join the broad-market Rus
PR Newswire · 06/22 10:30
Dosing underway in mid-stage study of Immunic's IMU-838 in COVID-19
Seeking Alpha - Article · 06/15 14:07
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
PR Newswire · 06/15 11:30
Immunic COVID-19 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/12 15:32
Why Immunic (IMUX) Stock Might be a Great Pick
Zacks · 06/11 13:32

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About IMUX

Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
More

Webull offers kinds of Immunic Inc stock information, including NASDAQ:IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.